<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CCAAT/enhancer binding proteins (C/EBPs) are a family of transcription factors that have been implicated in diverse cellular functions such as cellular differentiation and proliferation, and inflammatory processes </plain></SENT>
<SENT sid="1" pm="."><plain>C/EBPzeta, also known as GADD153, CHOP10, and DDIT3 has been found associated with the development of myxoid <z:hpo ids='HP_0012034'>liposarcoma</z:hpo> and the progression of <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate the correlation of C/EBPzeta transcript levels with the development of <z:hpo ids='HP_0001909'>leukemia</z:hpo>, samples from 187 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) were examined for C/EBPzeta <z:chebi fb="2" ids="33699">mRNA</z:chebi> using real-time quantitative PCR (RQ-PCR) </plain></SENT>
<SENT sid="3" pm="."><plain>RQ-PCR analysis demonstrated the median levels of C/EBPzeta were significantly decreased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and <z:mp ids='MP_0005481'>CML</z:mp> patients compared with <z:mpath ids='MPATH_458'>normal</z:mpath> controls (1.40, 0.96, 2.60 versus 14.69, P&lt;0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Significant differences were also observed between patients with <z:mp ids='MP_0005481'>CML</z:mp> and with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that the insufficient dosage of C/EBPzeta might be involved in the development of <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>